Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04818372
Recruitment Status : Recruiting
First Posted : March 26, 2021
Last Update Posted : November 12, 2021
Sponsor:
Information provided by (Responsible Party):
Keymed Biosciences Co.Ltd

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313.

The dose escalation part will determine the MTD of CM313 in subjects with relapsed and/or refractory multiple myeloma (RRMM) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design).

The dose expansion part includes two cohorts. Cohort 1 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Dexamethasone in subjects with RRMM. Cohort 2 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Rd regimen (Lenalidomide/Dexamethasone) in subjects with RRMM or newly diagnosed MM (NDMM).


Condition or disease Intervention/treatment Phase
Multiple Myeloma Lymphoma Drug: CM313-Dose escalation Drug: CM313 Drug: Dexamethasone Drug: Lenalidomide Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 87 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose Escalation: Modified 3+3 dose escalation design: an accelerated dose titration design followed by traditional 3+3 dose escalation design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Actual Study Start Date : April 26, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dose escalation

Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.

Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg).

 Drug: CM313-Dose escalation
Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
Experimental: Dose expansion _Cohort 1
This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
 Drug: CM313
Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.

Drug: Dexamethasone
dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Experimental: Dose expansion _Cohort 2
This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
 Drug: CM313
Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.

Drug: Dexamethasone
dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle

Drug: Lenalidomide
25 mg/day lenalidomide 21 of 28 days cycle


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT) [ Time Frame: Up to 21 days after the first dose ]
  2. Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 [ Time Frame: Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier ]
  3. Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients [ Time Frame: Up to 24 months ]
    ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.


Secondary Outcome Measures :
  1. Dose escalation: AUC to the last quantifiable concentration [AUC(0-last)], over the dosing interval [AUC(0-tau)], extrapolated to infinity [AUC(0-inf), time to Cmax (tmax), apparent half-life (t1/2), systemic clearance (CL). [ Time Frame: 21 days after the first dose ]
  2. Dose escalation and Dose expansion: AUC(0-last), AUC(0-tau), Cmax, t1/2, systemic clearance (CL), volume of distribution (Vz, Vss), minimum concentration (Cmin), Ctrough, accumulation ratios for Cmax and AUC(0-tau) for multiple doses [ Time Frame: up to 24 months ]
  3. Dose escalation and Dose expansion: Incidence of anti-CM313 [ Time Frame: up to 24 months ]
  4. Dose escalation: Overall Response Rate (ORR) [ Time Frame: up to 24 months ]
    ORR is defined as the proportion of participants who have a partial response (PR) or better according to the IMWG criteria.

  5. Dose escalation and Dose expansion: Clinical Benefit Rate (CBR) [ Time Frame: up to 24 months ]
    CBR is defined as the proportion of participants who have a minimal response (MR) or better according to the IMWG criteria.

  6. Dose escalation and Dose expansion: Duration of Response (DOR) [ Time Frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months) ]
    DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of PD, per IMWG criteria.or better according to the IMWG criteria.

  7. Dose escalation and Dose expansion: Time to Response (TTR) [ Time Frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months) ]
    TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.

  8. Dose escalation and Dose expansion: Progression-Free Survival (PFS) [ Time Frame: up to 24 months ]
    PFS is defined as time from date of first dose of study drug to date of first documented PD, per IMWG criteria, or death due to any cause, whichever occurs first.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Dose escalation: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies and subjects with recurrent and refractory lymphoma.
  • Dose expansion_cohort 1: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies.
  • Dose expansion_cohort 2: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies, or subjects with NDMM.
  • For MM: Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria.
  • For MM: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 gram per deciliter (g/dL) or urine M-protein level >=200 milligram per 24 hours (mg/24 h) or light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain (FLC) >= 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • Eastern Cooperative Oncology Group (ECOG) performance status score <＝2.
  • Women of childbearing potential and male subjects must agree to remain abstinent or use contraceptive methods as defined by the protocol.
  • Side effects of any prior therapy or procedures for any medical condition has recovered to NCI-CTCAE v.5.0 Grade ≤ 1.

Key Exclusion Criteria:

  • Previous treatment with any anti-CD38 therapy.
  • Subjects with concurrent plasma cell leukemia.
  • Received a cumulative dose of corticosteroids equivalent to greater than or equal to ( >=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication).
  • Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose.
  • Received an allogenic stem cell transplant or an autologous stem cell transplant within 3 months before first dose of study drug.
  • Central nervous system (CNS) involvement.
  • The forced expiratory volume in one second (FEV1)<60%.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04818372


Contacts
Layout table for location contacts
Contact: Qian Jia 028-88610620 qianjia@keymedbio.com
Contact: Dan Liu 028-88610620 danliu@keymedbio.com

Locations
Layout table for location information
China, Beijing
Beijing Chao-Yang Hospital, Capital Medical University (West Branch) Recruiting
Beijing, Beijing, China
Contact: Zhongxia Huang         
Beijing Chao-Yang Hospital Recruiting
Beijing, Beijing, China
Contact: Wenming Chen, Dr.    13910107759    13910107759@qq.com   
Peking University Third Hospital Not yet recruiting
Beijing, Beijing, China
Contact: Hongmei Jing, Dr.         
Sponsors and Collaborators
Keymed Biosciences Co.Ltd
Investigators
Layout table for investigator information
Principal Investigator: Wenming Chen, Dr. Beijing Chao Yang Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Keymed Biosciences Co.Ltd
ClinicalTrials.gov Identifier: NCT04818372    
Other Study ID Numbers: CM313MM001
First Posted: March 26, 2021    Key Record Dates
Last Update Posted: November 12, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
 Hemorrhagic Disorders
Dexamethasone
Lenalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors